| Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K Yamazaki, M Nagase, H Tamagawa, S Ueda, T Tamura, K Murata, ... Annals of Oncology 27 (8), 1539-1546, 2016 | 275 | 2016 |
| Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer S Matsusaka, K Chìn, M Ogura, M Suenaga, E Shinozaki, Y Mishima, ... Cancer science 101 (4), 1067-1071, 2010 | 166 | 2010 |
| TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm … Y Kuboki, T Nishina, E Shinozaki, K Yamazaki, K Shitara, W Okamoto, ... The Lancet Oncology 18 (9), 1172-1181, 2017 | 161 | 2017 |
| Clinical utility of circulating tumor DNA for colorectal cancer H Osumi, E Shinozaki, K Yamaguchi, H Zembutsu Cancer science 110 (4), 1148-1155, 2019 | 149 | 2019 |
| Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients N Fuse, Y Kuboki, T Kuwata, T Nishina, S Kadowaki, E Shinozaki, ... Gastric cancer 19, 183-191, 2016 | 139 | 2016 |
| Dlk-1, a cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency H Yanai, K Nakamura, S Hijioka, A Kamei, T Ikari, Y Ishikawa, E Shinozaki, ... The journal of biochemistry 148 (1), 85-92, 2010 | 118 | 2010 |
| Subjective and functional results after total gastrectomy: prospective study for longterm comparison of reconstruction procedures S Adachi, S Inagawa, T Enomoto, E Shinozaki, T Oda, T Kawamoto Gastric Cancer 6, 0024-0029, 2003 | 101 | 2003 |
| Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer H Osumi, E Shinozaki, K Yamaguchi, H Zembutsu Scientific reports 9 (1), 17358, 2019 | 96 | 2019 |
| Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer T Wakatsuki, N Yamamoto, T Sano, K Chin, H Kawachi, D Takahari, ... Journal of gastroenterology 53, 1186-1195, 2018 | 86 | 2018 |
| Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer H Osumi, E Shinozaki, Y Takeda, T Wakatsuki, T Ichimura, A Saiura, ... Cancer medicine 8 (1), 408-417, 2019 | 85 | 2019 |
| Immunotherapy in colorectal cancer: current and future strategies A Ooki, E Shinozaki, K Yamaguchi Journal of the Anus, Rectum and Colon 5 (1), 11-24, 2021 | 83 | 2021 |
| Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer H Bando, Y Nakamura, H Taniguchi, M Shiozawa, H Yasui, T Esaki, ... JCO Precision Oncology 6, e2100535, 2022 | 74 | 2022 |
| Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial) A Kawazoe, Y Kuboki, E Shinozaki, H Hara, T Nishina, Y Komatsu, S Yuki, ... Clinical Cancer Research 26 (22), 5887-5894, 2020 | 73 | 2020 |
| Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer … E Shinozaki, T Yoshino, K Yamazaki, K Muro, K Yamaguchi, T Nishina, ... British journal of cancer 117 (10), 1450-1458, 2017 | 73 | 2017 |
| Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer S Yagi, T Wakatsuki, N Yamamoto, K Chin, D Takahari, M Ogura, ... Gastric Cancer 22, 518-525, 2019 | 65 | 2019 |
| Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival Y Ota, D Takahari, T Suzuki, H Osumi, I Nakayama, A Oki, T Wakatsuki, ... Cancer Chemotherapy and Pharmacology 85, 265-272, 2020 | 64 | 2020 |
| Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study M Suenaga, N Mizunuma, S Matsusaka, E Shinozaki, M Ozaka, M Ogura, ... Drug design, development and therapy, 3099-3108, 2015 | 63 | 2015 |
| Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience K Chin, S Baba, H Hosaka, A Ishiyama, N Mizunuma, E Shinozaki, ... Japanese journal of clinical oncology 38 (6), 426-431, 2008 | 62 | 2008 |
| Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit H Bando, T Yoshino, E Shinozaki, T Nishina, K Yamazaki, K Yamaguchi, ... BMC cancer 13, 1-9, 2013 | 61 | 2013 |
| Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials T Yoshino, JM Cleary, E Van Cutsem, RJ Mayer, A Ohtsu, E Shinozaki, ... Annals of Oncology 31 (1), 88-95, 2020 | 60 | 2020 |
